Andrew Strong is an engineer, entrepreneur and lawyer. He’s also the president, CEO and general counsel of Kalon Biotherapeutics, a biotech company created in 2011 by the Texas A&M University System to do contract development and manufacture, of drugs for cancer treatment and vaccines for influenza and other infectious diseases.
“The first thing I did was go out and hire the best people I could find,” said Strong. Three years later, the company has more than 100 employees and is forecasting $20 million in revenue.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
